Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3221-3228

  Paulsen, Ørnulf ^a   Klepstad, Pål ^b   Rosland, Jan Henrik ^d   Aass, Nina ^e,f   Albert, Eva ^g   Fayers, Peter ^b,h   Kaasa, Stein ^c  

^a TELEMARK HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF OSLO   (Norway)

^g Sørlandet Hospital Kristiansand   (Norway)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; METHYLPREDNISOLONE; MORPHINE; OPIATE; PREGABALIN; GLUCOCORTICOID; NARCOTIC ANALGESIC AGENT;

ADULT; ADVANCED CANCER; ANALGESIA; ANALGESIC ACTIVITY; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BREAKTHROUGH PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; DYSPEPSIA; EDEMA; FEMALE; GYNECOLOGIC CANCER; HUMAN; INSOMNIA; KARNOFSKY PERFORMANCE STATUS; LOSS OF APPETITE; LUNG CANCER; MALE; METASTASIS; MOUTH DISEASE; MUSCLE WEAKNESS; PAIN INTENSITY; PATIENT SATISFACTION; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; AGED; ANOREXIA; CLINICAL TRIAL; COMPLICATION; FATIGUE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PAIN; PAIN MEASUREMENT; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; ANALGESICS, OPIOID; ANOREXIA; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84907495442     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.3926     Document Type: Article

References (39)

1. Klepstad P, Kaasa S, Cherny N, et al: Pain and pain treatments in European palliative care units: A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19:477-484, 2005
2. Raphael J, Ahmedzai S, Hester J, et al: Cancer pain: Part 1-Pathophysiology; oncological, pharmacological, and psychological treatments: A perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med 11:742-764, 2010
3. World Health Organization: WHO's cancer pain ladder for adults. http://www.who.int/cancer/palliative/painladder/en/
4. Knotkova H, Pappagallo M: Adjuvant analgesics. Anesthesiol Clin 25:775-786, vi, 2007
5. Fallon M, Hanks G, Cherny N: Principles of control of cancer pain. BMJ 332:1022-1024, 2006
6. Swarm RA, Abernethy AP, Anghelescu DL, et al: Adult cancer pain. J Natl Compr Canc Netw 11:992-1022, 2013
7. Lussier D, Portenoy RK: Adjuvant analgesics in pain management, in Hanks G, Cherny NI, Christakis NA, et al (eds): Oxford Textbook of Palliative Medicine (ed 4). New York, NY, Oxford University Press, 2010, pp 706-734
8. Zhang JM, An J: Cytokines, inflammation, and pain. Int Anesthesiol Clin 45:27-37, 2007
9. Watkins LR, Hutchinson MR, Milligan ED, et al: "Listening" and "talking" to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 56:148-169, 2007
10. Mensah-Nyagan AG, Meyer L, Schaeffer V, et al: Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology 34:S169-S177, 2009 (suppl 1)
11. Salerno A, Hermann R: Efficacy and safety of steroid use for postoperative pain relief: Update and review of the medical literature. J Bone Joint Surg Am 88:1361-1372, 2006
12. Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 69:751-754, 1985
13. Della Cuna GR, Pellegrini A, Piazzi M: Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: A placebocontrolled, multicenter study-The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25:1817-1821, 1989
14. Ryan R, Booth S, Price S: Corticosteroid-use in primary and secondary brain tumour patients: A review. J Neurooncol 106:449-459, 2012
15. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
16. Lundström SH, Fürst CJ: The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430-437, 2006
17. Paulsen Ø, Aass N, Kaasa S, et al: Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage 46:96-105, 2013
18. Radbruch L, Strasser F, Elsner F, et al: Fatigue in palliative care patients: An EAPC approach. Palliat Med 22:13-32, 2008
19. Yavuzsen T, Davis MP, Walsh D, et al: Systematic review of the treatment of cancerassociated anorexia and weight loss. J Clin Oncol 23:8500-8511, 2005
20. Caraceni A, Hanks G, Kaasa S, et al: Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-e68, 2012
21. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
22. Bruera E, Kuehn N, Miller MJ, et al: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 7:6-9, 1991
23. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual. http://groups.eortc.be/qol/manuals
25. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
26. Kaasa S, Apolone G, Klepstad P, et al: Expert conference on cancer pain assessment and classification: The need for international consensus-Working proposals on international standards. BMJ Support Palliat Care 1:281-287, 2011
27. Buccheri G, Ferrigno D, Tamburini M: Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32 A: 1135-1141, 1996
28. Twycross R, Wilcock A: Dextropropoxyphene: Palliative Care Formulary. Nottingham, United Kingdom, Palliativedrugs.com, 2011, pp 337-340
29. Peuckmann V, Elsner F, Krumm N, et al: Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 11:CD006788, 2010
30. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al: Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebocontrolled trial in patients with advanced cancer. J Clin Oncol 31:3076-3082, 2013
31. Moertel CG, Schutt AJ, Reitemeier RJ, et al: Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607-1609, 1974
32. Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients: The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 25:1823-1829, 1989
33. Willox JC, Corr J, Shaw J, et al: Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 288:27, 1984
34. Bruera E, Moyano JR, Sala R, et al: Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: A randomized controlled trial. J Pain Symptom Manage 28:381-388, 2004
35. Stanbury RM, Graham EM: Systemic corticosteroid therapy: Side effects and their management. Br J Ophthalmol 82:704-708, 1998
36. Fardet L, Kassar A, Cabane J, et al: Corticosteroid-induced adverse events in adults: Frequency, screening and prevention. Drug Saf 30:861-881, 2007
37. Braun TP, Zhu X, Szumowski M, et al: Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitaryadrenal axis. J Exp Med 208:2449-2463, 2011
38. Schakman O, Gilson H, Kalista S, et al: Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 72:36-41, 2009 (suppl 1)
39. Dietrich J, Rao K, Pastorino S, et al: Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol 4:233-242, 2011